New study below.
6-month treatment after primary treatment failure.
Seems odd to me - I wonder what they had in mind other than demonstrating an add-on benefit for bevacizumab?
This statement makes no sense to me:
"Patients were randomly assigned 2:1 to a luteinizing hormone-releasing hormone agonist (bicalutamide or bevacizumab) or ADT alone ...
- bicalutamide (Casodex) is an antiandrogen - not a luteinizing hormone-releasing hormone agonist, but often combined with one.
- bevacizumab (Avastin) is a very expensive angiogenesis inhibitor with a disappointing track record.
Elsewhere, the statement has been rephrased:
"Participants were randomly assigned 2:1 to receive bicalutamide as ADT plus bevacizumab or ADT alone ..."  Seems to confirm Casodex as ADT monotherapy!
"Relapse was defined as a PSA of more than 0.2 ng/mL for prostatectomy patients or PSA of more than 2.0 ng/mL for primary radiation therapy patients."
Time to relapse: 10.2 months for Casodex; 13.3 months for Casodex+Avastin.
"... key eligibility criteria included increasing PSA level (≤50 ng/mL), PSA doubling time <18 months, low-burden metastatic or nonmetastatic disease, and asymptomatic metastases (lymph nodes <3 cm, ≤5 bony metastases) ..." 
The same team had a paper last April:
"Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical relapse after definitive local therapy for prostate cancer" 
"Forty-one patients are included in the analysis. At one year following completion of ADT, 45% (n=13/29) and 29% (n=5/17) of patients with a testosterone ≥100 ng/dL and testosterone ≥ 240 ng/dL had a PSA < 0.2 ng/mL. The median follow-up is 27.5 months (inter-quartile range: 21.8, 38.1). Eight (20%) patients are free from PSA progression, 19 (46%) did not restart ADT, and 34 (83%) are free from metastasis. Sixteen (39%) patients experienced grade 3 and five (12%) experienced grade 4 toxicities."